Rhythm Pharmaceuticals Inc (RYTM) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $98.07
• Market Cap: $6.58B
• EPS: $-3.10
• 52-Week High: $122.20
• 52-Week Low: $45.91

Market Sentiment

Rhythm Pharmaceuticals Inc currently has a Bullish sentiment score of 0.20.

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company at the forefront of developing innovative therapies for rare genetic obesity disorders. Its flagship product, Imcivree (setmelanotide), uniquely addresses the biological mechanisms underlying severe obesity linked to specific genetic conditions, thereby offering transformative treatment options for underserved patient populations. With a strong foundation in melanocortin system research, Rhythm is strategically expanding...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Rhythm Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does RYTM pay dividends?

Rhythm Pharmaceuticals Inc (RYTM) does not currently pay a regular dividend.

What is RYTM's market cap?

Rhythm Pharmaceuticals Inc (RYTM) has a market capitalization of $6.58B with a current stock price of $98.07.